Home›People›Victoria Manax
Victoria Manax

Victoria Manax

Medical Officer and director at Duo Oncology.

Director
Updated Nov 9, 2026·Latest SEC filing Aug 7, 2026·Suggest an edit

About Victoria Manax

Victoria Manax is a medical officer and director at Duo Oncology.

Experience

This experience comes from Victoria Manax's profile and from SEC filings. For roles taken from filings, the years are when the filings name Victoria Manax in the role, so the role may have started earlier or lasted longer.

Avive Solutions Inc. Current
Board Observer
2024 – Present
Duo Oncology Inc. Current
Medical Officer and director
2023 – Present · Pittsburgh, PA
Develops combination chemotherapy medicines for people with cancer.
Immodulon Therapeutics Ltd Current
Board Member
2023 – Present
Invest Northern Ireland – Americas Current
Board Member
2023 – Present
Eckuity Capital Current
Founding General Partner
2022 – Present
TrovaNow Current
Board Member
2020 – Present
Manax Rutson Clinical Development, LLC Current
Co-Founder
2020 – Present
RUT-MAN HOLDINGS LLC Current
Principal
2005 – Present
MedSurgPI, LLC
Head of Oncology
2022 – 2023
Immunicom, Inc.
Chief Medical Officer
2021 – 2023
Pancreatic Cancer Action Network
Chief Medical Officer
2016 – 2020
Celgene
Executive Director, US Medical Affairs, Disease Lead GI Celgene
2010 – 2016
Abraxis BioScience
Medical Director, Medical Affairs
2007 – 2010
Conway Research Institute
Research Assistant
2000 – 2005

Key Colleagues at Startups

The people Victoria Manax works with at each company, as listed on that company's latest Form D.

Duo Oncology Inc. · Form D/A, Aug 7, 2026
JH
Jing-Zhou Hou
Co-Founder and director
Sam Rothstein
Sam Rothstein
CEO & Cofounder, director
ST
Stephen Thorne
Executive officer and promoter
Stanley Marks
Stanley Marks
Board Chairman
SL
Song Li
Co-Founder and director
Katherine Eichinger
Katherine Eichinger
Chief Operating Officer
Joe Gatto
Joe Gatto
Director
LL
Lusong Luo
Member - BeOne Medicines and director

Sources

  1. SECDuo Oncology Inc. Form D/A, filed Aug 7, 2026